The Prognostic Implications of the Histologic Subtype and the Expression of Phosphorylated ERK 1/2 in Papillary Renal Cell Carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Background : The authors of this study wanted to confirm the prognostic implication of the histologic subtype; further, we wanted to explore the expression of phosphorylated extracellular signal-regulated kinase 1/2 (pERK) in papillary renal cell carcinoma (PRCC) and determine its clinicopathologic and prognostic significance. Methods : A total of 45 patients who underwent nephrectomy for PRCC were enrolled in this study. The hematoxylin and eosin slides were reviewed and pERK immunohistochemistry was performed. Results : Type 2 PRCC was significantly correlated with a larger tumor size (p=0.030), a higher nuclear grade (p<0.001), a more advanced tumor stage (p=0.041) and more frequent distant metastasis(p=0.019). The tumors were pERK-low (0 and 1+) in 30 cases (66.7%) and pERK-high (2+) in 15 cases (33.3%). The pERK-high PRCC was significantly associated with a smaller tumor size (p=0.001) and an earlier tumor stage (p=0.004). On the univariate analysis, the histologic subtype, the TNM stage and the pERK status were significantly associated with progression- free survival (PFS). Multivariate analysis showed that the histologic subtype (hazard ratio 22.81, p=0.042) and the TNM stage (hazard ratio 23.48, p=0.009) were independent prognostic factors for PFS. Conclusions : Type 2 PRCC, together with the TNM stage, was identified as one of independent poor prognostic factors for PFS. The pERK status was a prognostic factor for PFS on the univariate analysis, but not on the multivariate analysis.
Abstract
Background : The authors of this study wanted to confirm the prognostic implication of the histologic subtype; further, we wanted to explore the expression of phosphorylated extracellular signal-regulated kinase 1/2 (pERK) in papillary renal cell carcinoma (PRCC) and determine its clinicopathologic and prognostic significance. Methods : A total of 45 patients who underwent nephrectomy for PRCC were enrolled in this study. The hematoxylin and eosin slides were reviewed and pERK immunohistochemistry was performed. Results : Type 2 PRCC was significantly correlated with a larger tumor size (p=0.030), a higher nuclear grade (p<0.001), a more advanced tumor stage (p=0.041) and more frequent distant metastasis(p=0.019). The tumors were pERK-low (0 and 1+) in 30 cases (66.7%) and pERK-high (2+) in 15 cases (33.3%). The pERK-high PRCC was significantly associated with a smaller tumor size (p=0.001) and an earlier tumor stage (p=0.004). On the univariate analysis, the histologic subtype, the TNM stage and the pERK status were significantly associated with progression- free survival (PFS). Multivariate analysis showed that the histologic subtype (hazard ratio 22.81, p=0.042) and the TNM stage (hazard ratio 23.48, p=0.009) were independent prognostic factors for PFS. Conclusions : Type 2 PRCC, together with the TNM stage, was identified as one of independent poor prognostic factors for PFS. The pERK status was a prognostic factor for PFS on the univariate analysis, but not on the multivariate analysis.
참고문헌 (30)
- Delahunt B, "Papillary renal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs", pp.27~29, 2004
- Patard JJ, "Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience", J Clin Oncol, 23, pp.2763~2771
- Beck SD, "Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma", Ann Surg Oncol, 11, pp.71~77 (2004)
- Delahunt B, "Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors", Mod Pathol, 10, pp.537~544 (1997)
- Shuch BM, "Prognostic factors in renal cell carcinoma", Semin Oncol, 33, pp.563~575 (2006)
- Mejean A, "Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality", J Urol, 170, pp.764~767 (2003)
- Yamashita S, "Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis", Int J Urol, 14, pp.679~683 (2007)
- Pignot G, "Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification", Urology, 69, pp.230~235 (2007)
- Pearson G, "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions", Endocr Rev, 22, pp.153~183 (2001)
- Hoshino R, "Constitutive activation of the 41-", 43-kDa mitogen-activated protein kinase signaling pathway in human tumors, 1999, pp.18, 813~822
- Inamoto T, "Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1", 2 inducible matrix metalloproteinases, 2007, pp.25, 574~583
- Huang D, "Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo", Cancer Res, 68, pp.81~88 (2008)
- Oka H, "Constitutive activation of mitogen- activated protein (MAP) kinases in human renal cell carcinoma", Cancer Res, 55, pp.4182~4187 (1995)
- Yang XJ, "A molecular classification of papillary renal cell carcinoma", Cancer Res, 65, pp.5628~5637 (2005)
- Fuhrman SA, "Prognostic significance of morphologic parameters in renal cell carcinoma", Am J Surg Pathol, 6, pp.655~663 (1982)
- Greene FL, "AJCC cancer staging manual. 6th ed", pp.323~328 (2002), Springer
- Kim H, "Renal cell carcinoma in South Korea: a multicenter study", Hum Pathol, 35, pp.1556~1563 (2004)
- Furge KA, "Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma", Cancer Res, 67, pp.3171~3176 (2007)
- Delahunt B, "Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases", Hum Pathol, 32, pp.590~595 (2001)
- Gunawan B, "Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors", Cancer Res, 63, pp.6200~6205 (2003)
- Schmitz K, "Activation of extracellular regulated kinases (ERK1", 2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations, 2007, pp.450, 151~159
- Schmitz KJ, "Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection", J Hepatol, 48, pp.83~90 (2008)
- Handra-Luca A, "Extra-cellular signal- regulated ERK-1", ERK-2 pathway activation in human Sslivary gland mucoepidermoid carcinoma: Association to Aggressive Tumor Behavior and Tumor Cell Proliferation, 2003, pp.163, 957~967
- Milde-Langosch K, "Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1", 2) in breast cancer, 2005, pp.92, 2206~2215
- Mizumoto Y, "Activation of ERK1", 2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis, 2007, pp.98, 652~658
- Hsu CY, "Characterization of active mitogen- activated protein kinase in ovarian serous carcinomas", Clin Cancer Res, 10, pp.6432~6436 (2004)
- Branca M, "Activation of the ERK", MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer, 2004, pp.122, 902~911
- Meloche S, "The ERK1", 2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition, 2007, pp.26, 3227~3239
- Robinson MJ, "A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation", Curr Biol, 8, pp.1141~1150 (1998)
- Tohgo A, "Betaarrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation", J Biol Chem, 227, pp.9429~9436 (2002)